Alvotech Completes Routine FDA Surveillance Inspection in Reykjavik

Inspection Concluded at Reykjavik Facility

Alvotech, a global biotech company focused on the development and manufacturing of biosimilar medicines, has officially announced the completion of a routine surveillance inspection conducted by the U.S. Food and Drug Administration (FDA). The inspection took place at the company's primary manufacturing site located in Reykjavik, Iceland.

Regulatory Context

Surveillance inspections are a standard component of the FDA's oversight process for pharmaceutical manufacturing facilities. These inspections are designed to ensure that companies maintain compliance with current Good Manufacturing Practice (cGMP) regulations. For Alvotech, maintaining a positive regulatory standing is critical as the company continues to advance its portfolio of biosimilar candidates intended for the U.S. market.

Operational Impact

The facility in Reykjavik serves as the hub for Alvotech's production capabilities. The company has previously stated that its interactions with regulatory bodies are a top priority to ensure the timely delivery of high-quality biosimilars to patients. Following the conclusion of this inspection, the company continues its focus on:

• Maintaining high standards of quality control and manufacturing excellence
• Advancing its pipeline of biosimilar products
• Collaborating with international regulatory agencies

Looking Ahead

While the inspection was categorized as routine, it represents a significant milestone in the company's ongoing efforts to meet the rigorous requirements set forth by the FDA. Alvotech remains committed to its mission of expanding patient access to affordable biologic therapies through its specialized manufacturing infrastructure in Iceland.